CARBOGEN AMCIS featured in Innovations in Pharmaceutical Technology: Rethinking Early-Phase Development for Speed and Long-Term Success

Marc Lanz, Head of Innovation, and Martin Althaus, Manager of Process R&D at CARBOGEN AMCIS, were featured in the Spring 2026 edition of Innovations in Pharmaceutical Technology magazine.

In their article, “Rethinking early phase development: how to move quickly without creating downstream risk,” they explore how today’s early-phase development is evolving under increasing pressure from competition, financing models, and regulatory expectations.

Their insights highlight the shift from prioritising speed alone to focusing on efficiency—ensuring rapid progress while building robust, scalable processes that support long-term success. They emphasize the importance of generating high-quality scientific data early, aligning early supply strategies with future manufacturability, and avoiding technical shortcuts that could create challenges later in development.

Marc and Martin also underline the growing role of integrated thinking and early CDMO involvement to balance urgency with scientific rigor, helping biotech companies reach proof of concept faster without compromising downstream outcomes.

Their perspectives reflect CARBOGEN AMCIS’ commitment to enabling smarter, more efficient drug development through expertise, collaboration, and forward-looking strategies.